Skip to main content

Table 5 Variables associated with OS in patients with primary resistance

From: BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

Variable

N

Median OS (in months)

Hazard ratio (95% CI)

p-value

IMDC score

 Favorable

5

–

–

–

 Intermediate

27

–

0.14 (0.03, 0.73)

0.02

 Poor

3

2.99

1.00

Ref

 N/A

3

6.51

0.51 (0.06, 4.50)

0.54

Pre-treatment NLR

27

13.51

1.17 (1.00, 1.36)

0.04